First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation.
Andrew Brenner, Jeffrey Infante, Manish Patel, Hendrik-Tobias Arkenau, Mark Voskoboynik, Erkut Borazanci, Gerald Falchook, L.R. Molife, Shubham Pant, Emma Dean, Lorraine Pelosof, Suzanne Jones, Chris Rubio, William McCulloch, Valentina Zhukova-Harrill, George Kemble, Marie O'Farrell, A. Burris III. Howard
Research output: Contribution to conference › Poster
Fingerprint
Dive into the research topics of 'First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation.'. Together they form a unique fingerprint.